Shares of Charles River Laboratories International, Inc. (CRL) have traded between $115.7 – 161.39. The next earnings date is set for Feb 12, 2020. Let’s see how its prospects are shaping up.

What does Charles River Laboratories International, Inc.(CRL) do?

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment, and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client’s use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

CRL Insider Trading Insight

On 2019-12-09, Johst David P Corporate EVP sold 24,660 shares of CRL. That represents a value of $212,854. Not to be outdone, on 2019-12-09, Girshick Birgit S – Sale sold1,051 shares of CRL. These insiders are clearly in the know because they work closely with the company.

The AKBA Consensus Price Target

The mean recommendation of Akebia Therapeutics, Inc. from top Wall Street analysts is a Strong Buy. That is based on 4 analysts who work on the Street. Based on 4 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $15.50 with a high forecast of $16.00 and a low forecast of $15.00. The average price target represents a 124.64% increase from the last price of $6.90. Last week, several articles were published in financial papers about AKBA and 32% Bearish while 68% Bullish.

AKBA Intraday Trading

AKBA is due to report earnings on Mar 24, 2020. In the last year the price has ranged from 2.99 – 9.31. Recently, Smith Cynthia purchased 15,000 shares of AKBA. He is a $19,894 shareholder in AKBA.

Looking for stocks similar to CRL and AKBA?

Here are some stocks to consider: